...
首页> 外文期刊>Bioconjugate Chemistry >Receptor-Targeted Liposomal Delivery of Boron-Containing Cholesterol Mimics for Boron Neutron Capture Therapy (BNCT)
【24h】

Receptor-Targeted Liposomal Delivery of Boron-Containing Cholesterol Mimics for Boron Neutron Capture Therapy (BNCT)

机译:含硼胆固醇模拟物的受体靶向脂质体递送,用于硼中子俘获治疗(BNCT)

获取原文
获取原文并翻译 | 示例

摘要

Liposomes have been a main focus of tumor-selective boron delivery strategies in boron neutron capture therapy (BNCT),a binary method for the treatment of cancer that is based on the nuclear reaction between boron atoms and low-energy thermal neutrons.Three novel carboranyl cholesterol derivatives were prepared as lipid bilayer components for the construction of nontargeted and receptor-targeted boronated liposomes for BNCT.A major structural feature of these novel boronated cholesterol mimics is the replacement of the B and the C ring of cholesterol with a carborane cluster.Computational analyses indicated that all three boronated compounds have structural features and physicochemical properties that are very similar to those of cholesterol.One of the synthesized boronated cholesterol mimics was stably incorporated into non-,folate receptor (FR)-,and vascular endothelial growth factor receptor-2 (VEGFR-2)-targeted liposomes.No major differences were found in appearance,size distribution,and lamellarity between conventional dipalmitoylphosphatidylcholine (DPPC)/cholesterol liposomes,nontargeted,and FR-targeted liposomal formulations of this carboranyl cholesterol derivative.FR-targeted boronated liposomes were taken up extensively in FR overexpressing KB cells in vitro,and the uptake was effectively blocked in the presence of free folate.In contrast,a boronated cholesterol mimic incorporated into nontargeted liposomes showed significantly lower cellular uptake.There was no apparent in vitro cytotoxicity in FR overexpressing KB cells and VEGFR-2 overexpressing 293/KDR cells when these were incubated with boronated FR-and (VEGFR-2)-targeted liposomes,respectively,although the former accumulated extensively in KB cells and the latter effectively interacted with VEGFR-2 by causing autophosphorylation and protecting 293/KDR cells from SLT (Shiga-like toxin)-VEGF cytotoxicity.
机译:脂质体一直是硼中子俘获疗法(BNCT)中肿瘤选择性硼释放策略的主要焦点,硼中子俘获疗法是一种基于硼原子与低能热中子之间的核反应而治疗癌症的二元方法。三种新颖的碳硼烷基胆固醇衍生物被制备为脂质双层成分,用于构建BNCT的非靶向和受体靶向的硼化脂质体。这些新型的硼化胆固醇模拟物的主要结构特征是用碳硼烷簇代替胆固醇的B和C环。分析表明,所有三种硼化的化合物都具有与胆固醇非常相似的结构特征和理化性质。一种合成的硼化的胆固醇模拟物被稳定地掺入了非叶酸受体(FR)-和血管内皮生长因子受体- 2(VEGFR-2)靶向脂质体。外观,大小分布无明显差异常规的二棕榈酰磷脂酰胆碱(DPPC)/胆固醇脂质体,非靶向和靶向FR的这种碳硼烷基胆固醇衍生物的脂质体制剂之间的层状性相比之下,掺入非靶向脂质体的硼化胆固醇模拟物显示出明显更低的细胞摄取.FR过度表达的KB细胞和VEGFR-2过度表达的293 / KDR细胞在体外没有明显的细胞毒性。分别用硼化的FR和(VEGFR-2)靶向脂质体,尽管前者在KB细胞中大量积累,而后者通过引起自身磷酸化并保护293 / KDR细胞免受SLT(类志贺毒素)的影响而与VEGFR-2有效相互作用。 -VEGF的细胞毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号